4,4-difluoro-1-nitrosopiperidine | 935259-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4,4-difluoro-1-nitrosopiperidine
• 英文别名: 4,4-Difluoro-1-nitrosopiperidine
• CAS: 935259-98-6
• 化学式: C₅H₈F₂N₂O
• 分子量: 150.128
• InChiKey: FFEFLYLLIDMFKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,4-difluoro-1-nitrosopiperidine 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以22%的产率得到4,4-二氟哌啶-1-胺
  参考文献：
  名称：

  作为SOS1抑制剂的杂环化合物

  摘要：

  本发明提供了作为SOS1抑制剂的化合物，具体地，本发明提供了一种如下式(I)所示结构的化合物，或其光学异构体，药学上可接受的盐，前药，氘代衍生物，水合物，溶剂合物。所述的化合物可以用于治疗或预防与SOS1的活性或表达量相关的疾病或病症。

  公开号：

  CN113200981A
• 作为产物：
  描述：

  4,4-二氟哌啶 在 溶剂黄146 、 sodium nitrite 作用下， 以 水 为溶剂， 生成 4,4-difluoro-1-nitrosopiperidine
  参考文献：
  名称：

  PYRIMIDOIMIDAZOLE COMPOUNDS USED AS DNA-PK INHIBITORS

  摘要：

  一类DNA-PK抑制剂，特别是由公式（IV）所表示的化合物或其药学上可接受的盐，以及其在制备与DNA-PK抑制剂相关的药物中的应用。

  公开号：

  EP4067359A1

文献信息

• 作为SOS1抑制剂的杂环化合物
  申请人：杭州英创医药科技有限公司

  公开号：CN113200981A

  公开（公告）日：2021-08-03

  本发明提供了作为SOS1抑制剂的化合物，具体地，本发明提供了一种如下式(I)所示结构的化合物，或其光学异构体，药学上可接受的盐，前药，氘代衍生物，水合物，溶剂合物。所述的化合物可以用于治疗或预防与SOS1的活性或表达量相关的疾病或病症。
• Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity
  申请人：Moritani Yasunori

  公开号：US20090048256A1

  公开（公告）日：2009-02-19

  The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R 1 and R 2 are the same or different and an optionally substituted aryl group etc., R 3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q 1 is a single bond, an alkylene group or a group of the formula: —N(R 7 )—, R 7 is a hydrogen atom or an alkyl group, Q 2 is a single bond, an oxygen atom or an alkylene group, R 4 is a cycloalkyl group, a group of the formula: —N(R 5 )(R 6 ) etc., one of R 5 and R 6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: —N(R 8 )(R 9 ) etc., D is an oxygen atom etc., R A1 is an amino group etc., R A2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R 8 and R 9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.

  本发明涉及一种具有强效CB1拮抗活性的吡唑化合物，具有以下式[I]：其中R1和R2相同或不同，且可以是取代的芳基等，R3是烷基等，E是以下式(i)至(iv)中的一种基团：Q1是单键，烷基或式：—N（R7）—的基团，R7是氢原子或烷基，Q2是单键，氧原子或烷基，R4是环烷基，式：—N（R5）（R6）等的基团，其中R5和R6中的一个是氢原子或烷基，另一个是烷基，式：—N（R8）（R9）等的基团，D是氧原子等，RA1是氨基等，RA2是可选取代的脂肪族杂环基团，R是烷基，可选取代为1至3个卤原子等，R8和R9中的一个是氢原子或烷基，另一个是烷基等，或其药学上可接受的盐。
• Pyrazolo[1,5-A]Pyrimidine Compounds
  申请人：Moritani Yasunori

  公开号：US20090069298A1

  公开（公告）日：2009-03-12

  The present invention relates to a novel pyrazolo[1,5-a]pyrimidine compound of the formula [I]: wherein R 1 and R 2 are the same or different and an optionally substituted aryl group etc. Q is single bond, a methylene group or a group of the formula: —N(R Q )—, R Q is an alkyl group, Ring A is a substituted pyrazole ring fused to the adjacent pyrimidine ring having the following formula (A), (B) or (C), R 3 and R 4 are the same or different and a hydrogen atom, a cyano group etc. E is one of the following groups (i) to (v): R 00 is an alkyl group, Q 1 is a single bond etc., Q 2 is a single bond or an alkylene group, one of R 5 and R 6 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., one of R 50 and R 60 is a hydrogen atom or an alkyl group and the other is a hydrogen atom, an alkyl group etc., R 51 is an alkyl group or an optionally substituted arylsulfonyl group, R 61 is an alkylamino group or an azido group, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种新型吡唑并[1,5-a]嘧啶化合物，其化学式为[I]：其中R1和R2相同或不同，可以是任选取代芳基等；Q是单键，亚甲基基团或式子：—N(RQ)—，RQ是烷基基团；环A是一个取代的吡唑环与相邻的嘧啶环融合，具有以下式子(A)、(B)或(C)：其中R3和R4相同或不同，可以是氢原子、氰基等；E是以下式子(i)至(v)中的一种：其中R00是烷基基团，Q1是单键等，Q2是单键或烷基烃基团，R5和R6中的一个是氢原子或烷基基团，另一个是烷基基团等，R50和R60中的一个是氢原子或烷基基团，另一个是氢原子、烷基基团等，R51是烷基基团或任选取代的芳基磺酰基团，R61是烷基氨基基团或叠氮基团，或其药学上可接受的盐。
• Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US07872006B2

  公开（公告）日：2011-01-18

  The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc., R3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q1 is a single bond, an alkylene group or a group of the formula: —N(R7)—, R7 is a hydrogen atom or an alkyl group, Q2 is a single bond, an oxygen atom or an alkylene group, R4 is a cycloalkyl group, a group of the formula: —N(R5)(R6) etc., one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: —N(R8)(R9) etc., D is an oxygen atom etc., RA1 is an amino group etc., RA2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R8 and R9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.

  本发明涉及一种具有强CB1拮抗活性的吡唑化合物，其具有以下式[I]：其中R1和R2相同或不同，可选地取代芳基等；R3是烷基等；E是以下式(i)到(iv)中的一种基团：Q1是单键，烷基或式：—N(R7)—的基团，R7是氢原子或烷基；Q2是单键，氧原子或烷基；R4是环烷基，式：—N(R5)(R6)等的基团，R5和R6中的一个是氢原子或烷基，另一个是烷基，式：—N(R8)(R9)等的基团；D是氧原子等；RA1是氨基等；RA2是可选取代的脂肪族杂环基团；R是烷基，可选地被一个到三个卤原子等取代；R8和R9中的一个是氢原子或烷基，另一个是烷基等；或其药学上可接受的盐。
• Pyrazolo[1,5-A]pyrimidine compounds
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08188097B2

  公开（公告）日：2012-05-29

  The present invention relates to a novel pyrazolo[1,5-a]pyrimidine compound of the formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc. Q is single bond, a methylene group or a group of the formula: —N(RQ)—, RQ is an alkyl group, Ring A is a substituted pyrazole ring fused to the adjacent pyrimidine ring having the following formula (A), (B) or (C), R3 and R4 are the same or different and a hydrogen atom, a cyano group etc. E is one of the following groups (i) to (v): R00 is an alkyl group, Q1 is a single bond etc., Q2 is a single bond or an alkylene group, one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., one of R50 and R60 is a hydrogen atom or an alkyl group and the other is a hydrogen atom, an alkyl group etc., R51 is an alkyl group or an optionally substituted arylsulfonyl group, R61 is an alkylamino group or an azido group, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种新的嘧唑并[1,5-a]嘧啶化合物，其化学式为[I]，其中R1和R2相同或不同，可选取取代基的芳基等。Q为单键，亚甲基基或式子为：—N(RQ)—的基团，RQ为烷基。环A是一个取代的嘧唑环，与相邻的嘧啶环融合，其具有以下式子（A）、（B）或（C）：R3和R4相同或不同，可选取氢原子，氰基等。E是以下化合物组之一：（i）至（v）中的一种：R00为烷基，Q1为单键等，Q2为单键或烷基亚基，R5和R6中的一个为氢原子或烷基，另一个为烷基等，R50和R60中的一个为氢原子或烷基，另一个为氢原子，烷基等，R51为烷基或可选取取代基的芳基磺酰基，R61为烷基氨基基团或偶氮基团，或其药学上可接受的盐。